Literature DB >> 9455884

Antibody to Pneumocystis carinii protects rats and mice from developing pneumonia.

M S Bartlett1, W C Angus, M M Shaw, P J Durant, C H Lee, J M Pascale, J W Smith.   

Abstract

Well-proven mouse and rat models were used to show that polyclonal antisera to Pneumocystis carinii protect against P. carinii pneumonia. Antibodies were obtained from animals that were allowed to recover from severe P. carinii pneumonia after immunosuppression had been stopped and which then were given a booster injection of P. carinii from the same animal species. Mice immunosuppressed with corticosteroids or antibodies to L3T4+ lymphocytes (which are comparable to CD4 cells of humans) and transtracheally inoculated with mouse P. carinii did not develop P. carinii pneumonia if they were passively immunized with antiserum, while mice immunosuppressed and inoculated by identical procedures but not given antibodies developed severe infections. Rats immunosuppressed with corticosteroids and inoculated with rat P. carinii had less severe infections if they were given rat anti-P. carinii antisera. The polyclonal antisera developed in mice provided greater protection for the mice than the polyclonal rat antisera did for the rats; however, the potencies and compositions of the antisera were not quantitated and probably differed. Since both rats and mice can be protected from P. carinii infections with polyclonal antisera, it may be possible to develop vaccines that will elicit protective antibodies in humans.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9455884      PMCID: PMC121395          DOI: 10.1128/CDLI.5.1.74-77.1998

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  29 in total

1.  Inoculated mouse model of Pneumocystis carinii infection.

Authors:  M S Bartlett; S F Queener; M M Durkin; M A Shaw; J W Smith
Journal:  Diagn Microbiol Infect Dis       Date:  1992-02       Impact factor: 2.803

2.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

3.  Pneumocystis carinii pneumonitis, eosinophilia and hypogammaglobulinemia.

Authors:  N Pattison; T Wright; H G Herrod
Journal:  Pediatr Infect Dis J       Date:  1987-03       Impact factor: 2.129

4.  Protein-calorie malnutrition. A host determinant for Pneumocystis carinii infection.

Authors:  W T Hughes; R A Price; F Sisko; W S Havron; A G Kafatos; M Schonland; P M Smythe
Journal:  Am J Dis Child       Date:  1974-07

5.  Pneumocystis carinii: improved models to study efficacy of drugs for treatment or prophylaxis of Pneumocystis pneumonia in the rat (Rattus spp.).

Authors:  M S Bartlett; J A Fishman; M M Durkin; S F Queener; J W Smith
Journal:  Exp Parasitol       Date:  1990-01       Impact factor: 2.011

6.  Polyamine content of Pneumocystis carinii and response to the ornithine decarboxylase inhibitor DL-alpha-difluoromethylornithine.

Authors:  S Merali; A B Clarkson
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

Review 7.  Preventing Pneumocystis carinii pneumonia in persons infected with human immunodeficiency virus.

Authors:  R J Simonds; W T Hughes; J Feinberg; T R Navin
Journal:  Clin Infect Dis       Date:  1995-08       Impact factor: 9.079

8.  Pneumocystis carinii pneumonia among patients without AIDS at a cancer hospital.

Authors:  K A Sepkowitz; A E Brown; E E Telzak; S Gottlieb; D Armstrong
Journal:  JAMA       Date:  1992-02-12       Impact factor: 56.272

9.  Comparison of corticosteroid- and L3T4+ antibody-immunosuppressed mouse models of Pneumocystis carinii pneumonia for evaluation of drugs and leukocytes.

Authors:  M S Bartlett; W L Current; A Orazi; N L Bauer; R S Neiman; S F Queener; J W Smith
Journal:  Clin Diagn Lab Immunol       Date:  1994-09

10.  Requirement for CD4+ cells in resistance to Pneumocystis carinii pneumonia in mice.

Authors:  A G Harmsen; M Stankiewicz
Journal:  J Exp Med       Date:  1990-09-01       Impact factor: 14.307

View more
  8 in total

Review 1.  Immunological features of Pneumocystis carinii infection in humans.

Authors:  P D Walzer
Journal:  Clin Diagn Lab Immunol       Date:  1999-03

2.  Human immunodeficiency virus-infected patients with prior Pneumocystis pneumonia exhibit increased serologic reactivity to several major surface glycoprotein clones.

Authors:  K R Daly; J V Koch; N J Shire; L Levin; P D Walzer
Journal:  Clin Vaccine Immunol       Date:  2006-10

3.  Passive intranasal monoclonal antibody prophylaxis against murine Pneumocystis carinii pneumonia.

Authors:  Francis Gigliotti; Constantine G Haidaris; Terry W Wright; Allen G Harmsen
Journal:  Infect Immun       Date:  2002-03       Impact factor: 3.441

Review 4.  Colonization by Pneumocystis jirovecii and its role in disease.

Authors:  Alison Morris; Karen A Norris
Journal:  Clin Microbiol Rev       Date:  2012-04       Impact factor: 26.132

5.  Primary pneumocystis infection in infants hospitalized with acute respiratory tract infection.

Authors:  Hans Henrik Larsen; Marie-Louise von Linstow; Bettina Lundgren; Birthe Høgh; Henrik Westh; Jens D Lundgren
Journal:  Emerg Infect Dis       Date:  2007-01       Impact factor: 6.883

6.  Pneumocystis colonization in immunocompetent and simian immunodeficiency virus-infected cynomolgus macaques.

Authors:  Heather M Kling; Timothy W Shipley; Sangita Patil; Alison Morris; Karen A Norris
Journal:  J Infect Dis       Date:  2009-01-01       Impact factor: 5.226

7.  Geographical variation in serological responses to recombinant Pneumocystis jirovecii major surface glycoprotein antigens.

Authors:  K Daly; J Koch; N Respaldiza; C de la Horra; M A Montes-Cano; F J Medrano; J M Varela; E J Calderon; P D Walzer
Journal:  Clin Microbiol Infect       Date:  2009-03-21       Impact factor: 8.067

Review 8.  Pneumocystis Pneumonia: Immunity, Vaccines, and Treatments.

Authors:  Aaron D Gingerich; Karen A Norris; Jarrod J Mousa
Journal:  Pathogens       Date:  2021-02-19
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.